Track topics on Twitter Track topics that are important to you
Patients with diabetic macular edema recalcitrant to anti-VEGF therapy and then treated with an intravitreal sustained-release 0.7 mg dexamethasone implant as part of a multimodal treatment experienced significant gains in visual acuity at a mean follow-up of 6 months, according to a study.DME is a multifaceted disease with ischemic and inflammatory mechanisms that can be treated with Ozurdex (dexamethasone intravitreal implant, Allergan), Zainab Khan, BHSc, MD, FRCSC, told Ocular Surgery News.
Original Article: Ozurdex works as adjunct treatment in diabetic macular edemaNEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...